Advertisement

Fever and Abdominal Pain

  • Esraa M. Eloseily
  • Randy Q. CronEmail author
Chapter

Abstract

  • Macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition

  • MAS is usually diagnosed in febrile intensive care unit patients

  • MAS can mimic septic shock, systemic inflammatory response syndrome (SIRS), or multi-organ dysfunction syndrome (MODS)

  • Timely diagnosis and early treatment are crucial to improve survival

  • Serum ferritin is usually highly elevated and will assist in recognizing secondary HLH/MAS in critically ill febrile patients

  • Bone marrow hemophagocytosis, although common, is not an essential feature for diagnosis, and its absence should not delay the start of an appropriate treatment

  • IL-1 inhibition with anakinra has been reported to be safe and efficacious in non-malignancy related forms of secondary HLH and MAS

Keywords

Macrophage activation syndrome Hemophagocytic lymphohistiocytosis Systemic inflammatory response syndrome Multi-organ dysfunction syndrome 

References

  1. 1.
    Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22(5):561–6.CrossRefGoogle Scholar
  2. 2.
    Atteritano M, David A, Bagnato G, Beninati C, Frisina A, Iaria C, Cascio A. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci. 2012;16(10):1414–24.PubMedGoogle Scholar
  3. 3.
    Wong K-F, Hui P-K, Chan JK, Chan Y-W, Ha S-Y. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114(5):387–90.CrossRefGoogle Scholar
  4. 4.
    Voskoboinik I, Sutton VR, Ciccone A, House CM, Chia J, Darcy PK, Yagita H, Trapani JA. Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. Blood. 2007;110(4):1184–90.CrossRefGoogle Scholar
  5. 5.
    Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133–8.PubMedGoogle Scholar
  6. 6.
    Sawhney S, Woo P, Murray K. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–6.CrossRefGoogle Scholar
  7. 7.
    Stephan J, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40(11):1285–92.CrossRefGoogle Scholar
  8. 8.
    Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRefGoogle Scholar
  9. 9.
    Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies HC. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat. 2006;27(1):62–8.CrossRefGoogle Scholar
  10. 10.
    Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14(5):548–52.CrossRefGoogle Scholar
  11. 11.
    Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, Voskoboinik I, Trapani JA. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307–17.CrossRefGoogle Scholar
  12. 12.
    Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009;221(05):278–85.CrossRefGoogle Scholar
  13. 13.
    Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum. 2004;50(3):689–98.CrossRefGoogle Scholar
  14. 14.
    Saltzman RW, Monaco-Shawver L, Zhang K, Sullivan KE, Filipovich AH, Orange JS. Novel mutation in syntaxin-binding protein 2 (STXBP2) prevents IL-2-induced natural killer cell cytotoxicity. J Allergy Clin Immunol. 2012;129(6):1666.CrossRefGoogle Scholar
  15. 15.
    Spessott WA, Sanmillan ML, McCormick ME, Patel N, Villanueva J, Zhang K, Nichols KE, Giraudo CG. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood. 2015;125(10):1566–77.CrossRefGoogle Scholar
  16. 16.
    Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li H, Walter MR, De Benedetti F, Grom AA, Cron RQ. A Heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol. 2016;196:2492–503.Google Scholar
  17. 17.
    Zhang X-Y, Ye X-W, Feng D-X, Han J, Li D, Zhang C. Hemophagocytic lymphohistiocytosis induced by severe pandemic influenza A (H1N1) 2009 virus infection: a case report. Case Rep Med. 2011;2011:951910.CrossRefGoogle Scholar
  18. 18.
    Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res. 1998;44(4):465–8.CrossRefGoogle Scholar
  19. 19.
    Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2004;7(1):1.Google Scholar
  20. 20.
    Caiello I, Minnone G, Holzinger D, Vogl T, Prencipe G, Manzo A, De Benedetti F, Strippoli R. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS One. 2014;9(10):e107886.CrossRefGoogle Scholar
  21. 21.
    Zhang M, Behrens EM, Atkinson TP, Shakoory B, Grom AA, Cron RQ. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep. 2014;16(9):439.CrossRefGoogle Scholar
  22. 22.
    Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277–92.CrossRefGoogle Scholar
  23. 23.
    Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol. 2014;26(5):562.CrossRefGoogle Scholar
  24. 24.
    Chen C, Huang Y, Jaing T, Hung I, Yang C, Chang L, Lin T. Hemophagocytic syndrome: a review of 18 pediatric cases. J Microbiol Immunol Infect. 2004;37(3):157.PubMedGoogle Scholar
  25. 25.
    Elazary AS, Wolf DG, Amir G, Avni B, Rund D, Yehuda DB, Sviri S. Severe Epstein–Barr virus-associated hemophagocytic syndrome in six adult patients. J Clin Virol. 2007;40(2):156–9.CrossRefGoogle Scholar
  26. 26.
    Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007;29(8):569–73.CrossRefGoogle Scholar
  27. 27.
    Milone MC, Tsai DE, Hodinka RL, Silverman LB, Malbran A, Wasik MA, Nichols KE. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell–directed therapy. Blood. 2005;105(3):994–6.CrossRefGoogle Scholar
  28. 28.
    Henter J-I, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.CrossRefGoogle Scholar
  29. 29.
    Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23–7.CrossRefGoogle Scholar
  30. 30.
    Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4(11):615–20.CrossRefGoogle Scholar
  31. 31.
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, Van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–55.CrossRefGoogle Scholar
  32. 32.
    Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38(1):180–1.CrossRefGoogle Scholar
  33. 33.
    Cron RQ, Chatham WW. Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. Clin Exp Rheumatol. 2016;34(5):953.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of PediatricsUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Division of Rheumatology, Department of PediatricsAssiut University Children’s HospitalAssiutEgypt

Personalised recommendations